[PDF][PDF] Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163.
SL Ellard, M Clemons, KA Gelmon, B Norris… - Clin Oncol, 2009 - researchgate.net
Clin Oncol, 2009•researchgate.net
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With
Recurrent/Metastatic Breast Cancer: NCIC Clinic Page 1 Randomized Phase II Study
Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer:
NCIC Clinical Trials Group IND.163 Susan L. Ellard, Mark Clemons, Karen A. Gelmon, Brian
Norris, Hagen Kennecke, Stephen Chia, Kathleen Pritchard, Andrea Eisen, Ted Vandenberg,
Marianne Taylor, Eric Sauerbrei, Moshe Mishaeli, David Huntsman, Wendy Walsh, Martin Olivo …
Recurrent/Metastatic Breast Cancer: NCIC Clinic Page 1 Randomized Phase II Study
Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer:
NCIC Clinical Trials Group IND.163 Susan L. Ellard, Mark Clemons, Karen A. Gelmon, Brian
Norris, Hagen Kennecke, Stephen Chia, Kathleen Pritchard, Andrea Eisen, Ted Vandenberg,
Marianne Taylor, Eric Sauerbrei, Moshe Mishaeli, David Huntsman, Wendy Walsh, Martin Olivo …
Purpose
To evaluate the safety and efficacy of oral everolimus, a mammalian target of rapamycin (mTOR) inhibitor, in two different schedules in minimally pretreated patients with metastatic breast cancer and to explore for possible biologic correlates of response.
researchgate.net